Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence

Polymyxin B has resurged in recent years as a last resort therapy for Gram-negative multidrug-resistant (MDR) and extremely drug resistant (XDR) infections. Understanding newer evidence on polymyxin B is necessary to guide clinical decision making. Here, we present a literature review of polymyxin B...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Suneel Kumar, Singh, Omender, Juneja, Deven, Tyagi, Niraj, Khurana, Amandeep Singh, Qamra, Amit, Motlekar, Salman, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518490/
https://www.ncbi.nlm.nih.gov/pubmed/28761764
http://dx.doi.org/10.1155/2017/3635609
Descripción
Sumario:Polymyxin B has resurged in recent years as a last resort therapy for Gram-negative multidrug-resistant (MDR) and extremely drug resistant (XDR) infections. Understanding newer evidence on polymyxin B is necessary to guide clinical decision making. Here, we present a literature review of polymyxin B in Gram-negative infections with update on its pharmacology.

Ejemplares similares